Latest News

Novo Nordisk joins Evotec as drug discovery partner

Hamburg headquarters of Evotec AG. © Evotec


by tg

Novo Nordisk and Evotec have joined forces to find new drugs in the lucrative diabetes and obesity markets.

The companies announced that they will also seek to find drug candidates to treat co-morbidities such as diabetic kidney disease, nonalcoholic steatohepatitis and cardiovascular diseases. Under the agreement, Evotec will apply its small molecule  drug discovery platform, especially in ligand-based design, to find promising drug candidates to treat patients with diabetes and obesity. Once suitable preclinical candidates are selected, Novo Nordisk will use Evotec’s INDiGO platform – a tech portfolio to assess ADMET acquired for €62m in 2016 by the acquisition of Cyprotec – to move through pre-clinical studies to enter IND registration.

No financial details of the deal were disclosed. However, usual conditions of similar Evotec deals included €1m-10m R&D grants, €150m in milestones per compound and 8% tiered royalties on average. The deal adds new projects to Evotec's portfolio of more than 60 R&D co-owned projects.

Novo Nordisk is a leader in diabetes medicines.The chronic incapacitating disease, which affected about 425 million people worldwide in 2017 (2015: 415 million) and a market of US$727bn, is associated with chronic co-morbidities such as cardiovascular diseases, kidney diseases, nerve damage and eye diseases. Obesity affects more than 650 million adults worldwide and is often cited as a major risk factor for many diseases such as cardiovascular diseases, diabetes, musculoskeletal disorders, and several cancers. Treatment cost in 2017 were estimated over US$800bn in 2017 and is rising steeply.

Belgian eTheRNA raises €39m in Series B2 financing

Existing investors, including LSP (now EQT Life Sciences), PMV, Grand Pharma, Fund+, Omega Fund, and others, also participated in the financing....

AI expert XUND GmbH bags €6m seed financing

The Austrian start-up XUND GmbH  has succeeded in convincing high-profile investors from the pharmaceutical, digital health, hospital and...

EU Health Union ignoring cardiology

While the EU has already presented rules to establish a European Health Data Space (EHDS) and Europe’s Plan against Cancer within its Medicines...

Mablink raises $31m in Series A financing

Lyon-based Mablink Bioscience SAsaid it will use the proceeds primarily to advance its lead candidate MBK-103 to the clinical testing state and to...

Healthcare investments in Catalonia at record high

According to the 2021 BioRegion of Catalonia Report, the medical technology sector attracted most of the money, fueled by two large operations....

DAMAN P/S enters personal RA medicine project

Affecting more than three million patients in the EU and 17.6 million worldwide, Rheumatoid Arthritis (RA) has a massive impact on patients’ quality...

Resolve Biosciences secures US$71m in funding

The current Series B financing brings Mohnheim-based Resolve Biosciences’ financing up to a total of more than $100m. The finance round followed the...